Business
Medicure to Hold Investor Call on November 21, 2016
Medicure to Hold Investor Call on November 21, 2016 Medicure to Hold Investor Call...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure to Hold Investor Call on November 21, 2016\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedicure to Hold Investor Call on November 21, 2016\nCanada NewsWire\nWINNIPEG, Nov. 18, 2016\n\n\n\nWINNIPEG, Nov. 18, 2016 /CNW/ - Medicure Inc. (\"Medicure\") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will hold a conference call and webcast regarding the November 18, 2016 announcement surrounding the option exercise to acquire a majority interest in Apicore and the related debt transaction on Monday, November 21, 2016, at 10:30 AM Central Time (11:30 AM Eastern Time).\n\nConference Call Info:\n\nTopic:  Acquisition of Majority Interest in Apicore\n\nCall date:  Monday, November 21, 2016\n\nTime:  10:30 AM Central Time (11:30 AM Eastern Time)\n\nCanada toll-free:  1 (888) 465-5079   (Canada Toll: 1 (416) 216-4169)\n\nUnited States toll-free:  1 (888) 545-0687\n\nPasscode:  7552479# \n\nWebcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors.html  \n\nYou may request international country-specific access information by e-mailing the company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the company's website.\n\nAbout Medicure Inc.\n\nMedicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market.  The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc.  For more information on Medicure please visit www.medicure.com.\n\nAbout Apicore\n\nApicore is a leading process R&D and API man...